Rx PHARMASIST.CA
The Pharmasist newsletter

Stay current in
Canadian pharmacy.

Pharmacy news, practice updates and fresh perspectives—delivered to your inbox.

Keep your practice informed

  • Canadian pharmacy news

    Follow the developments shaping the profession.

  • Prescriber updates

    Stay informed about newly licensed Ontario physicians.

  • What's new on Pharmasist

    Explore new resources, tools and learning opportunities.

Free newsletter

A useful addition to your inbox.

We'll send a confirmation link first. Privacy policy

Amide-type local anesthetic

Bupivacaine

Marcaine

Dosage form
Tablet
Available strengths
2.5 mg/mL, 5 mg/mL and 7.5 mg/mL (as bupivacaine hydrochloride); 7.5 mg/mL hyperbaric solution in dextrose (Marcaine Spinal); 2.5 mg/mL and 5 mg/mL with epinephrine 1:200, 000 (Marcaine E)
Drug class
Amide-type local anesthetic
Common brand
Marcaine

Clinical overview. Bupivacaine (Marcaine) is a long-acting amide-type local anesthetic given by injection to numb a specific area of the body for surgery, labour, dental, and other procedures through nerve blocks, epidural, or spinal anesthesia. It works by blocking nerve signal transmission and is administered only by trained healthcare professionals in a properly equipped setting. Because bupivacaine can cause serious central nervous system and cardiovascular toxicity if it enters the bloodstream, dosing, injection technique, and patient monitoring are carefully controlled.

Indication

Common therapeutic uses

  • Bupivacaine produces local or regional anesthesia and analgesia for local infiltration procedures.
  • It is used for peripheral nerve blocks.
  • It is used for retrobulbar block during eye surgery.
  • It is used for caudal, epidural, and subarachnoid (spinal) blocks, including in surgical and obstetric settings.

Pregnancy

Risk assessment and monitoring considerations

  • Bupivacaine crosses the placenta and should be used during pregnancy only if the expected benefit justifies the potential risk to the fetus.
  • The highest 0.75% isotonic concentration is not recommended for obstetrical anesthesia because of reports of cardiac arrest that was difficult to resuscitate.
  • Bupivacaine is not used for obstetric paracervical block anesthesia because of the risk of fetal bradycardia and death.
  • Animal studies at high doses showed reduced offspring survival and embryo loss, though no adequate controlled studies exist in pregnant women.

Breastfeeding

Infant exposure considerations

  • Bupivacaine passes into breast milk in only very small amounts and is not expected to affect a breastfed infant at usual therapeutic doses.
  • It is not known whether the epinephrine in Marcaine E passes into breast milk, but it is unlikely to affect a nursing infant.

Geriatrics

Dosing and tolerability considerations

  • Older adults should receive reduced doses of bupivacaine based on their age and physical condition, since safety and effectiveness may differ in this population.
  • Dosage should also be reduced in debilitated or acutely ill patients regardless of age.

Pediatrics

Use in children and adolescents

  • Bupivacaine is not recommended for children younger than two years of age because Health Canada has not authorized its use in this age group due to insufficient data.
  • The 0.75% isotonic solution without epinephrine is not recommended for children under 12 years.
  • Marcaine Spinal (0.75% hyperbaric solution) is not recommended for spinal anesthesia in patients younger than 18 years.
  • For children over two years, doses are calculated by body weight, generally up to 2 mg/kg, adjusted for the type of block, age, and the child's condition.

Dosage & Administration

Practical dosing and administration

  • For local infiltration and peripheral nerve blocks, adult doses of the 0.25% or 0.5% solution are individualized based on the procedure, generally up to 150 mg per injection, and not exceeding 400 mg in 24 hours.
  • For epidural anesthesia, adults typically receive incremental doses of the 0.25% or 0.5% solution given a few millilitres at a time, with a test dose given first to check for accidental intravascular or spinal placement.
  • For spinal anesthesia, Marcaine Spinal (0.75% hyperbaric solution in dextrose) is dosed according to the extent of anesthesia required, from about 6 to 8 mg for low or saddle blocks up to 12 to 15 mg for high spinal blocks.
  • The 0.75% concentration is reserved for epidural block in abdominal surgery requiring complete muscle relaxation and for retrobulbar block; it is not recommended for obstetrical epidural anesthesia.
  • A single dose generally provides adequate anesthesia for most procedures; if repeat dosing is needed, it should not be given more often than every 3 to 6 hours.
  • Elderly, debilitated, or hepatically impaired patients should receive reduced doses.

Overdose

Recognizing and responding to overdose

If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.

  • Overdose or accidental injection of bupivacaine into a blood vessel causes central nervous system toxicity first, with symptoms such as numbness around the mouth, tingling, lightheadedness, ringing in the ears, and visual disturbances.
  • More severe central nervous system toxicity can cause slurred speech, muscle twitching or tremors, and may progress to loss of consciousness and generalized convulsions.
  • Severe overdose can cause cardiovascular toxicity, including low blood pressure, a slow heart rate, abnormal heart rhythms, and cardiac arrest, which usually follows the central nervous system signs.
  • Management involves immediately stopping the injection and establishing an open airway with assisted ventilation using 100% oxygen.
  • Convulsions are treated with an intravenous benzodiazepine or barbiturate, and a muscle relaxant may be used to help secure the airway.
  • Cardiovascular collapse is managed with intravenous fluids, vasopressors such as ephedrine or epinephrine, and cardiopulmonary resuscitation if cardiac arrest occurs, which may require prolonged resuscitative efforts.

Common side effects

Frequently reported tolerability concerns

  • Low blood pressure may occur, especially after epidural or spinal blocks, due to blockade of sympathetic nerves.
  • A slower than normal heart rate (bradycardia) may occur during epidural or spinal anesthesia.
  • Nausea and vomiting may occur, often related to a drop in blood pressure.
  • Headache may occur after spinal anesthesia.
  • Mild tingling, numbness, or a metallic taste in the mouth may occur as an early sign of rising blood levels of bupivacaine.
  • Dizziness or lightheadedness may occur.
  • Difficulty passing urine may occur after epidural or spinal blocks.
  • Restlessness, anxiety, or tremors may occur.

Serious side effects

Findings that may require urgent assessment

Serious side effects require immediate discussion with the prescriber or emergency care.

  • Bupivacaine can cause serious allergic reactions, including hives, swelling, and in rare cases anaphylactic shock.
  • Cardiac arrest and death have occurred with epidural or peripheral nerve block use of bupivacaine, in some cases despite prompt resuscitation efforts.
  • Severe, prolonged convulsions can occur with high blood levels of bupivacaine, risking oxygen deprivation.
  • High or total spinal blockade can cause extensive loss of movement and sensation, very low blood pressure, and respiratory paralysis.
  • Nerve damage, including persistent numbness, weakness, or in rare cases cauda equina syndrome (loss of bowel, bladder, or leg function), has been reported after regional anesthesia.
  • Aseptic meningitis, with fever and neck stiffness, has rarely been reported after spinal anesthesia.
  • Serious liver injury, including hepatic failure and jaundice, has been reported, particularly with repeated injections or prolonged infusions.
  • Irreversible breakdown of joint cartilage (chondrolysis) has been reported when local anesthetics were infused directly into a joint after surgery, which is not an approved use of bupivacaine.
  • Temporary or permanent vision loss and other eye complications can occur rarely after retrobulbar block.
  • Seek urgent medical attention for chest pain, fainting, a very slow or irregular heartbeat, severe shortness of breath, or convulsions.

Use with caution

Situations requiring closer assessment

  • Use with caution in patients with impaired cardiovascular function, since bupivacaine may further slow the heart's conduction system.
  • Use with caution in patients with heart block, since local anesthetics can worsen conduction problems.
  • Use with caution in patients with severe liver disease, since bupivacaine is metabolized by the liver and may build up to toxic levels.
  • Use with caution in patients with severe kidney dysfunction.
  • Use with caution in elderly or debilitated patients, who require reduced doses.
  • Use with caution when performing retrobulbar or head-and-neck blocks, since even small doses injected there can cause systemic-type toxicity.
  • Use with caution in patients with a history of sulfite sensitivity when using Marcaine E, which contains sodium metabisulfite.
  • Use with caution in patients with peripheral vascular disease when a vasoconstrictor-containing solution is being considered.
  • Use with caution in patients with poorly controlled hyperthyroidism or advanced diabetes when using Marcaine E.

Contraindications

Situations where therapy may be inappropriate

  • Contraindicated in patients with known hypersensitivity to bupivacaine or other amide-type local anesthetics.
  • Contraindicated for intravenous regional anesthesia (Bier block), since tourniquet leakage can cause systemic toxicity, cardiac arrest, or death.
  • Contraindicated for obstetric paracervical block anesthesia due to the risk of fetal bradycardia and death.
  • Contraindicated in patients in severe shock.
  • Contraindicated in patients with heart block.
  • Contraindicated when there is inflammation or infection near the injection site.
  • Marcaine multidose vials, which contain methylparaben, are contraindicated in patients allergic to ester-type local anesthetics or para-aminobenzoic acid (PABA).
  • Marcaine E is contraindicated in patients with hypersensitivity to sodium metabisulfite.

Drug interactions

Clinically relevant combinations

  • Using bupivacaine together with other local anesthetics, such as lidocaine, ropivacaine, mepivacaine, or prilocaine, increases the risk of additive toxic effects.
  • Concurrent use with structurally related antiarrhythmic drugs, such as procainamide, disopyramide, tocainide, mexiletine, and flecainide, may increase toxicity risk.
  • Caution and ECG monitoring are advised with class III antiarrhythmics such as amiodarone, since cardiac effects may be additive.
  • Marcaine E (with epinephrine) should not be used together with ergot-type oxytocic drugs, since this can cause severe, persistent high blood pressure.
  • Marcaine E combined with monoamine oxidase (MAO) inhibitors may cause severe, prolonged high blood pressure.
  • Marcaine E combined with tricyclic antidepressants may cause severe, prolonged high blood pressure.
  • Phenothiazines and butyrophenones may blunt or reverse epinephrine's effect, causing low blood pressure and a fast heart rate when used with Marcaine E.
  • Sedatives combined with bupivacaine may have an additive central nervous system depressant effect.
  • General anesthetic inhalation agents, such as halothane, used together with epinephrine-containing solutions can increase the risk of heart rhythm disturbances.
  • Cimetidine, and to a lesser extent ranitidine, can reduce clearance of bupivacaine and increase the risk of toxicity.
  • Non-selective beta-blockers such as propranolol can enhance the pressor effects of epinephrine in Marcaine E, raising the risk of severe high blood pressure and a slow heart rate.
  • Prior use of chloroprocaine or other local anesthetics before bupivacaine may interfere with its effect and is not recommended.

Food interactions

Meal-related administration

  • Bupivacaine is given by injection during a medical procedure, not swallowed, so there is no food or meal-timing interaction to consider.

Time of administration

Practical scheduling

  • Bupivacaine is administered by a physician or anesthesiologist at the time of the procedure requiring anesthesia, not on a fixed daily schedule.
  • The timing and any repeat dosing depend on the type of block and length of the procedure, with repeat doses, if needed, generally spaced 3 to 6 hours apart.
  • Because bupivacaine is not taken by mouth, there is no relationship between meals and when it is administered.

Storage

Product handling

  • Store Marcaine, Marcaine Spinal, and Marcaine E at room temperature, between 20°C and 25°C.
  • Do not freeze.
  • Protect Marcaine E from light due to the heat- and light-sensitivity of epinephrine.
  • Do not use if the solution appears discoloured or contains visible particles.

Patient take-away

Key counselling points for a quick closing summary

  • Marcaine is a local anesthetic given by injection to numb a specific area of the body for surgery, dental work, labour, or pain relief procedures.
  • It is administered only by trained healthcare professionals in a properly equipped setting.
  • Tell your healthcare provider about any allergies to local anesthetics, sulfites, or parabens before receiving Marcaine.
  • Report any tingling around the mouth, ringing in the ears, dizziness, or other unusual sensations immediately during or after the injection, since these can be early warning signs that need prompt attention.
  • Movement, sensation, or blood pressure changes in the treated area are expected and temporary, but you should tell your care team about anything that feels wrong.

References

Source material and product information

  1. Health Canada Product Monograph — Bupivacaine

For professional reference. Confirm patient-specific decisions against the current approved product monograph and applicable clinical guidance.

Rejoining the server...

Rejoin failed... trying again in seconds.

Failed to rejoin.
Please retry or reload the page.

The session has been paused by the server.

Failed to resume the session.
Please retry or reload the page.